Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PARN | O95453 | 1/20 | 0.39 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743588 | 0.84 | GDA (0.47) | GDAMEN1KMT2APDE5AGAA | |
| SCHEMBL5988838 | 0.68 | PDE5A (0.47) | MEN1KMT2APDE5AGAAPKM | |
| SCHEMBL21499645 | 0.67 | GDA (0.46) | GDAMEN1KMT2APARNCNOT7 | |
| SCHEMBL3990677 | 0.64 | MEN1 (1.00) | MEN1KMT2AGAATSHREP300 | |
| SCHEMBL8714088 | 0.64 | MEN1 (1.00) | MEN1KMT2AGAATSHREP300 | |
| SCHEMBL2435698 | 0.64 | MEN1 (1.00) | MEN1KMT2AGAATSHREP300 | |
| SCHEMBL2435977 | 0.64 | MEN1 (1.00) | MEN1KMT2AGAATSHREP300 | |
| SCHEMBL1503988 | 0.64 | MEN1 (1.00) | MEN1KMT2AGAATSHREP300 | |
| SCHEMBL14189454 | 0.64 | MEN1 (1.00) | MEN1KMT2AGAATSHREP300 | |
| SCHEMBL22105567 | 0.63 | TSHR (0.45) | GDAPARNCNOT7GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241065-A1 | Ring-expanded nucleosides and nucleotides | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2006-10-26 | — | — | US | disclosed |
| EP-1227103-B1 | Ring-expanded nucleosides and nucleotides | NABI (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20040077564-A1 | Ring expanded nucleosides and nucleotides | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2004-04-22 | — | — | US | disclosed |
| US-6677310-B1 | ANTICARCINOGENIC AGENTS; BACTERICIDES, FUNGICIDES, PARASITICIDES; VIRICIDES AGAINST HEPATITIS, EPSTEIN-BARR, CYTOMEGALO AND HUMAN IMMUNODEFICIENCY VIRUS | NABI | 2004-01-13 | — | — | US | disclosed |
| EP-0724587-B1 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | NABI (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1227103-A2 | Ring-expanded nucleosides and nucleotides | Nabi (US) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241065-A1 | Ring-expanded nucleosides and nucleotides | PNP, UMPS, ADA | GDA 53/4885MEN1 2103/4885KMT2A 1767/4885 |
| US-20040077564-A1 | Ring expanded nucleosides and nucleotides | PNP, PAICS, UMPS | GDA 49/4885MEN1 2287/4885KMT2A 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.